(Q64360391)

English

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

In more languages
default for all languages
No label defined

No description defined

Statements

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (English)
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
Eugeania Burch
0 references
Grace L Chen
0 references
Sandra Vazquez
0 references
Frank Arnold
0 references
Heather Lawlor
0 references
Jason Gall
0 references
Robert T Bailer
0 references
2 March 2019
0 references
0 references
393
0 references
10174
0 references
889-898
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit